Cargando…
Correction to: Cost-Effectiveness of Once-Weekly Semaglutide 1 mg versus Canaglifozin 300 mg in Patients with Type 2 Diabetes Mellitus in a Canadian Setting
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9206918/ https://www.ncbi.nlm.nih.gov/pubmed/35441978 http://dx.doi.org/10.1007/s40258-022-00734-z |
| _version_ | 1784729419381735424 |
|---|---|
| author | Stafford, Sara Bech, Peter G. Fridhammar, Adam Miresashvili, Nino Nilsson, Andreas Willis, Michael Liu, Aiden |
| author_facet | Stafford, Sara Bech, Peter G. Fridhammar, Adam Miresashvili, Nino Nilsson, Andreas Willis, Michael Liu, Aiden |
| author_sort | Stafford, Sara |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9206918 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Springer International Publishing |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-92069182022-06-21 Correction to: Cost-Effectiveness of Once-Weekly Semaglutide 1 mg versus Canaglifozin 300 mg in Patients with Type 2 Diabetes Mellitus in a Canadian Setting Stafford, Sara Bech, Peter G. Fridhammar, Adam Miresashvili, Nino Nilsson, Andreas Willis, Michael Liu, Aiden Appl Health Econ Health Policy Correction Springer International Publishing 2022-04-20 2022 /pmc/articles/PMC9206918/ /pubmed/35441978 http://dx.doi.org/10.1007/s40258-022-00734-z Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
| spellingShingle | Correction Stafford, Sara Bech, Peter G. Fridhammar, Adam Miresashvili, Nino Nilsson, Andreas Willis, Michael Liu, Aiden Correction to: Cost-Effectiveness of Once-Weekly Semaglutide 1 mg versus Canaglifozin 300 mg in Patients with Type 2 Diabetes Mellitus in a Canadian Setting |
| title | Correction to: Cost-Effectiveness of Once-Weekly Semaglutide 1 mg versus Canaglifozin 300 mg in Patients with Type 2 Diabetes Mellitus in a Canadian Setting |
| title_full | Correction to: Cost-Effectiveness of Once-Weekly Semaglutide 1 mg versus Canaglifozin 300 mg in Patients with Type 2 Diabetes Mellitus in a Canadian Setting |
| title_fullStr | Correction to: Cost-Effectiveness of Once-Weekly Semaglutide 1 mg versus Canaglifozin 300 mg in Patients with Type 2 Diabetes Mellitus in a Canadian Setting |
| title_full_unstemmed | Correction to: Cost-Effectiveness of Once-Weekly Semaglutide 1 mg versus Canaglifozin 300 mg in Patients with Type 2 Diabetes Mellitus in a Canadian Setting |
| title_short | Correction to: Cost-Effectiveness of Once-Weekly Semaglutide 1 mg versus Canaglifozin 300 mg in Patients with Type 2 Diabetes Mellitus in a Canadian Setting |
| title_sort | correction to: cost-effectiveness of once-weekly semaglutide 1 mg versus canaglifozin 300 mg in patients with type 2 diabetes mellitus in a canadian setting |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9206918/ https://www.ncbi.nlm.nih.gov/pubmed/35441978 http://dx.doi.org/10.1007/s40258-022-00734-z |
| work_keys_str_mv | AT staffordsara correctiontocosteffectivenessofonceweeklysemaglutide1mgversuscanaglifozin300mginpatientswithtype2diabetesmellitusinacanadiansetting AT bechpeterg correctiontocosteffectivenessofonceweeklysemaglutide1mgversuscanaglifozin300mginpatientswithtype2diabetesmellitusinacanadiansetting AT fridhammaradam correctiontocosteffectivenessofonceweeklysemaglutide1mgversuscanaglifozin300mginpatientswithtype2diabetesmellitusinacanadiansetting AT miresashvilinino correctiontocosteffectivenessofonceweeklysemaglutide1mgversuscanaglifozin300mginpatientswithtype2diabetesmellitusinacanadiansetting AT nilssonandreas correctiontocosteffectivenessofonceweeklysemaglutide1mgversuscanaglifozin300mginpatientswithtype2diabetesmellitusinacanadiansetting AT willismichael correctiontocosteffectivenessofonceweeklysemaglutide1mgversuscanaglifozin300mginpatientswithtype2diabetesmellitusinacanadiansetting AT liuaiden correctiontocosteffectivenessofonceweeklysemaglutide1mgversuscanaglifozin300mginpatientswithtype2diabetesmellitusinacanadiansetting |